Acute Lymphocytic Leukemia Market, Size, Share, Trends, Epidemiology Forecast till 2030

Posted on
by

Acute Lymphocytic Leukemia Market, Size, Share, Trends, Epidemiology Forecast till 2030

DelveInsight Business Research LLP
DelveInsight’s “Acute lymphocytic leukemia Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Acute lymphocytic leukemia (ALL), historical and forecasted epidemiology as well as the Acute lymphocytic leukemia (ALL) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Acute Lymphocytic Leukemia (ALL) is a type of cancer that affects the blood and bone marrow. It starts from young white blood cells called lymphocytes in the bone marrow; mainly characterized by an overproduction of immature white blood cells, called lymphoblasts or leukemic blasts.

 

Acute Lymphocytic Leukemia Epidemiology Segmentation 

  • Total Incident Cases of Leukemia
  • Total Incident Cases of ALL
  • Total Incident Cases of ALL Segmented by Age and Gender
  • Total Subtype-specific Cases of ALL
  • Total Genetic Mutation-specific Cases of ALL
  • Total Treated Cases of ALL

 

Acute Lymphocytic Leukemia Epidemiology

  • The total incident cases of ALL in the 7MM in 2017 was 10,341 
  • ALL is more frequent in males compare to females.
  • The total incident cases of ALL in 2017:-
  • The United States – 5,816
  • Germany – 942
  • France  – 857
  • Spain – 414
  • Japan – 872
  • The Age-Specific Incident Cases was the most in age-group

 

Acute Lymphocytic Leukemia Market

 

Acute Lymphocytic Leukemia market size in the 7MM in 2017 was USD 1,246 million

 

 

 

Acute Lymphocytic Leukemia Market Drivers

  • Increasing Focus Towards the Development of Targeted Therapies
  • Rising Occurrence of ALL
  • Improvement in the Diagnosis and Awareness
  • Competitive Landscape

 

Acute Lymphocytic Leukemia Market Barriers

  • Financial Impact
  • Generic Erosion
  • High Rate of Chemo resistance Development

 

Acute Lymphocytic Leukemia Emerging Therapies

  1. Imbruvica (Ibrutinib): Pharmacyclics (an AbbVie Company)
  2. Jakafi (ruxolitinib): Incyte Corporation/Novartis
  3. Motixafortide (BL-8040): BioLine Rx
  4. TC-110: TCR2 Therapeutics
  5. Lisocabtagene Maraleucel (JCAR017): Bristol-Myers Squibb
  6. TBI-1501: Takara Bio/Otsuka Pharmaceuticals
  7. UCART19: Servier/Allogene
  8.  Venetoclax: AbbVie and Roche
  9. NiCord (omidubicel): Gamida Cell Ltd.
  10.  Eliquis (apixaban): Bristol-Myers Squibb|Pfizer
  11. Isatuximab: Sanofi
  12.  JZP-458 (recombinant Erwinia asparaginase): Jazz Pharmaceuticals
  13.  Vyxeos (Daunorubicin and Cytarabine for Injection): Jazz Pharmaceuticals
  14.  Daratumumab: Janssen Research & Development
  15.  ProTmune: Fate Therapeutics
  16. MB-CART19.1: MiltenyiBiotec B.V. & Co. KG
  17.  BPX-501 T Cells (rivogenlecleucel; iC9-CAR19 cells): Bellicum Pharmaceuticals
  18. PBCAR0191: Precision BioSciences/Servier
  19.  AUTO1: Autolus Limited
  20. KTE-X19: Gilead Sciences

 

Request for sample pages

Table of contents

1. Key Insights

2. Executive Summary of Acute lymphocytic leukemia (ALL)

3. Competitive Intelligence Analysis for Acute lymphocytic leukemia (ALL)

4. Acute lymphocytic leukemia (ALL): Market Overview at a Glance

4.1. Acute lymphocytic leukemia (ALL) Total Market Share (%) Distribution in 2017

4.2. Acute lymphocytic leukemia (ALL) Total Market Share (%) Distribution in 2030

5. Acute lymphocytic leukemia (ALL): Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms 

5.3. Pathophysiology 

5.4. Risk Factors 

5.5. Diagnosis 

6. Patient Journey

7. Acute lymphocytic leukemia (ALL) Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Acute lymphocytic leukemia (ALL) Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Acute lymphocytic leukemia (ALL) Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Acute lymphocytic leukemia (ALL) Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Acute lymphocytic leukemia (ALL) Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Acute lymphocytic leukemia (ALL) Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Acute lymphocytic leukemia (ALL) Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Acute lymphocytic leukemia (ALL) Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Acute lymphocytic leukemia (ALL) Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Acute lymphocytic leukemia (ALL) Treatment and Management

8.2. Acute lymphocytic leukemia (ALL) Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Acute lymphocytic leukemia (ALL) Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Acute lymphocytic leukemia (ALL): Seven Major Market Analysis

13.1. Key Findings

13.2. Acute lymphocytic leukemia (ALL) Market Size in 7MM

13.3. Acute lymphocytic leukemia (ALL) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Acute lymphocytic leukemia (ALL) Total Market Size in the United States

15.1.2. Acute lymphocytic leukemia (ALL) Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Acute lymphocytic leukemia (ALL) Total Market Size in Germany

15.3.2. Acute lymphocytic leukemia (ALL) Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Acute lymphocytic leukemia (ALL) Total Market Size in France

15.4.2. Acute lymphocytic leukemia (ALL) Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Acute lymphocytic leukemia (ALL) Total Market Size in Italy

15.5.2. Acute lymphocytic leukemia (ALL) Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Acute lymphocytic leukemia (ALL) Total Market Size in Spain

15.6.2. Acute lymphocytic leukemia (ALL) Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Acute lymphocytic leukemia (ALL) Total Market Size in the United Kingdom

15.7.2. Acute lymphocytic leukemia (ALL) Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Acute lymphocytic leukemia (ALL) Total Market Size in Japan

15.8.3. Acute lymphocytic leukemia (ALL) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Acute lymphocytic leukemia (ALL)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/